Literature DB >> 20697850

What's new in the treatment of cocaine addiction?

Kyle M Kampman1.   

Abstract

Cocaine dependence continues to be a significant public health problem in the United States. The number of regular cocaine users has not declined significantly in the United States since 1992. Although counseling remains the treatment of choice for cocaine dependence, many cocaine-dependent patients do not respond completely to standard drug counseling. Therefore, the development of new and more effective treatments for cocaine dependence is a research priority. Progress in the understanding of the neurobiology of cocaine dependence has led to the discovery of several promising medications that have already shown encouraging results in controlled clinical trials. Other promising compounds are just becoming available for clinical trials. The use of novel psychosocial techniques such as contingency management seems to increase the efficacy of several medications used to treat cocaine dependence. New medications and new psychosocial techniques are leading to significant improvements in the treatment of cocaine dependence.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20697850     DOI: 10.1007/s11920-010-0143-5

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  47 in total

Review 1.  Glutamatergic agents for cocaine dependence.

Authors:  Charles Dackis; Charles O'Brien
Journal:  Ann N Y Acad Sci       Date:  2003-11       Impact factor: 5.691

2.  Human therapeutic cocaine vaccine: safety and immunogenicity.

Authors:  Thomas R Kosten; Marc Rosen; Julian Bond; Michael Settles; John St Clair Roberts; John Shields; Lindsay Jack; Barbara Fox
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

3.  The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats.

Authors:  Zheng-Xiong Xi; Amy Hauck Newman; Jeremy G Gilbert; Arlene C Pak; Xiao-Qing Peng; Charles R Ashby; Leah Gitajn; Eliot L Gardner
Journal:  Neuropsychopharmacology       Date:  2005-10-05       Impact factor: 7.853

4.  Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial.

Authors:  T P George; M C Chawarski; J Pakes; K M Carroll; T R Kosten; R S Schottenfeld
Journal:  Biol Psychiatry       Date:  2000-06-15       Impact factor: 13.382

5.  Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy.

Authors:  O A Petroff; F Hyder; R H Mattson; D L Rothman
Journal:  Neurology       Date:  1999-02       Impact factor: 9.910

Review 6.  The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders.

Authors:  P Sokoloff; J Diaz; B Le Foll; O Guillin; L Leriche; E Bezard; C Gross
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-02       Impact factor: 4.388

7.  Smoked cocaine self-administration is decreased by modafinil.

Authors:  Carl L Hart; Margaret Haney; Suzanne K Vosburg; Eric Rubin; Richard W Foltin
Journal:  Neuropsychopharmacology       Date:  2007-06-13       Impact factor: 7.853

8.  Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial.

Authors:  Kathleen M Carroll; Lisa R Fenton; Samuel A Ball; Charla Nich; Tami L Frankforter; Julia Shi; Bruce J Rounsaville
Journal:  Arch Gen Psychiatry       Date:  2004-03

9.  Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial.

Authors:  F Gerard Moeller; Joy M Schmitz; Joel L Steinberg; Charles M Green; Christopher Reist; Lingo Y Lai; Alan C Swann; John Grabowski
Journal:  Am J Drug Alcohol Abuse       Date:  2007       Impact factor: 3.829

10.  Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A.

Authors:  Patricia Di Ciano; Rachel J Underwood; Jim J Hagan; Barry J Everitt
Journal:  Neuropsychopharmacology       Date:  2002-06-18       Impact factor: 7.853

View more
  18 in total

Review 1.  Accelerating cocaine metabolism as an approach to the treatment of cocaine abuse and toxicity.

Authors:  Charles W Schindler; Steven R Goldberg
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

Review 2.  Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications.

Authors:  Rita Z Goldstein; Nora D Volkow
Journal:  Nat Rev Neurosci       Date:  2011-10-20       Impact factor: 34.870

3.  Dose-dependent effects of wheel running on cocaine-seeking and prefrontal cortex Bdnf exon IV expression in rats.

Authors:  Alexis B Peterson; Jean M Abel; Wendy J Lynch
Journal:  Psychopharmacology (Berl)       Date:  2013-10-31       Impact factor: 4.530

4.  Effects of chronic binge-like ethanol consumption on cocaine self-administration in rhesus monkeys.

Authors:  Paul W Czoty
Journal:  Drug Alcohol Depend       Date:  2015-05-21       Impact factor: 4.492

Review 5.  Treatment of substance abusing patients with comorbid psychiatric disorders.

Authors:  Thomas M Kelly; Dennis C Daley; Antoine B Douaihy
Journal:  Addict Behav       Date:  2011-09-14       Impact factor: 3.913

6.  Sex Differences, Cocaine Use, and Liver Fibrosis Among African Americans in the Miami Adult Studies on HIV Cohort.

Authors:  Gustavo Zarini; Sabrina Sales Martinez; Adriana Campa; Kenneth Sherman; Javier Tamargo; Jacqueline Hernandez Boyer; Colby Teeman; Angelique Johnson; Abraham Degarege; Pedro Greer; Qingyun Liu; Yongjun Huang; Raul Mandler; David Choi; Marianna K Baum
Journal:  J Womens Health (Larchmt)       Date:  2020-01-31       Impact factor: 2.681

Review 7.  Roles of nucleus accumbens CREB and dynorphin in dysregulation of motivation.

Authors:  John W Muschamp; William A Carlezon
Journal:  Cold Spring Harb Perspect Med       Date:  2013-02-01       Impact factor: 6.915

8.  Role of phenmetrazine as an active metabolite of phendimetrazine: evidence from studies of drug discrimination and pharmacokinetics in rhesus monkeys.

Authors:  Matthew L Banks; Bruce E Blough; Timothy R Fennell; Rodney W Snyder; S Stevens Negus
Journal:  Drug Alcohol Depend       Date:  2012-12-01       Impact factor: 4.492

9.  S-(N, N-diethylcarbamoyl)glutathione (carbamathione), a disulfiram metabolite and its effect on nucleus accumbens and prefrontal cortex dopamine, GABA, and glutamate: a microdialysis study.

Authors:  Morris D Faiman; Swetha Kaul; Shaheen A Latif; Todd D Williams; Craig E Lunte
Journal:  Neuropharmacology       Date:  2013-07-26       Impact factor: 5.250

Review 10.  Psychosocial interventions for psychostimulant misuse.

Authors:  Silvia Minozzi; Rosella Saulle; Franco De Crescenzo; Laura Amato
Journal:  Cochrane Database Syst Rev       Date:  2016-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.